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blood via immunomagnetic separation; monocyte expres-
sion of M2 markers (Dectin-1: 2.6 ± 1.9-fold; IL-10: 
3.0 ± 2.8-fold) significantly increased, whilst the expres-
sion of the M1 marker MCP-1 significantly decreased 
(0.83 ± 0.2 cf. basal), over the duration of the programme. 
Serum PPARγ activity levels and PPARγ target-genes 
(CD36: 1.9 ± 1.5-fold; LXRα: 5.0 ± 4.7-fold) were sig-
nificantly increased after the 8 week exercise programme. 
Associated with these effects were significant improve-
ments in systemic insulin sensitivity (McAuley’s ISI: 
Δ0.98 M/mU/L cf. basal).
Conclusion Exercise participation suppressed M1 mark-
ers and induced M2 markers in monocytes, potentially via 
PPARγ-triggered signalling, and these effects may contrib-
ute (perhaps via priming of monocytes for differentiation 
into M2 tissue-macrophages) to improved systemic insulin 
sensitivity in exercising participants. These findings pro-
vide an alternative mechanism by which exercise may exert 
its anti-inflammatory effects in order to prevent insulin 
resistance and type 2 diabetes.
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Abbreviations
ABCA1  ATP-binding cassette transporter
COX2  Cyclooxygenase 2
CD36  Cluster of differentiation 36
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase
IL  Interleukin
ISI  Insulin sensitivity index
LXRα  Liver x receptor alpha
MCP-1  Macrophage chemotactic protein-1
PPARγ  Peroxisome proliferator activated receptor 
gamma
Abstract 
Purpose Monocytes may be primed towards differentiation 
into classically activated M1 macrophages or alternatively 
activated M2 macrophages. M1 macrophages greatly con-
tribute to the inflammation which promotes insulin resist-
ance, whereas M2 macrophages resolve inflammation. We 
have previously shown that exercise increases M2 marker 
expression in mixed mononuclear cells, possibly via acti-
vation of the nuclear transcription factor PPARγ. How-
ever, these effects have not been demonstrated specifically 
within monocytes. Thus, we aimed to investigate whether 
moderate-intensity exercise elicited similar effects on 
monocytic M1/M2 marker expression and PPARγ activity 
to those reported previously in mononuclear cells, so as to 
further elucidate the mechanisms by which exercise may 
alter inflammatory status and, accordingly, prevent insulin 
resistance.
Methods/results 19 sedentary females completed an 
8 week moderate-intensity exercise programme (walk-
ing 45 min, thrice weekly). Monocytes were isolated from 
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RLU  Relative light units
TNFα  Tumour necrosis factor alpha
T2D  Type 2 diabetes
Introduction
Insulin resistance is a prerequisite for the development 
of type 2 diabetes (T2D) (Defronzo and Tripathy 2009; 
Petersen et al. 2007) with its pathogenesis being strongly 
associated with the development of chronic local and sys-
temic inflammation (Goldfine et al. 2013; Samuel and 
Shulman 2012). It has previously been shown that indi-
viduals with insulin resistance have a chronically elevated 
inflammatory status (Harford et al. 2011; Olefsky and 
Glass 2010), with some inflammatory mediators directly 
impairing insulin signalling by activating protein kinases 
to induce deleterious alternative phosphorylation of insu-
lin signalling molecules (Olefsky and Glass 2010). Taken 
together, it is clear that chronic inflammation plays a key 
role in the development of insulin resistance and T2D.
Physical activity has long been known to aid in the pre-
vention and management of insulin resistance, whereas 
a sedentary lifestyle is associated with increased risk of 
metabolic disease (Colberg et al. 2010). Several key studies 
have demonstrated that exercise training may prevent T2D 
incidence by approximately 50 %, either as a lone therapy 
(Pan et al. 1997) or in combination with other lifestyle 
interventions such as diet counselling or weight loss (Dia-
betes Prevention Program Research Group 2002; Eriksson 
et al. 1999). Interestingly, the effects of lifestyle modifi-
cation appear to be stronger than those achieved with the 
pharmacological intervention of metformin (Knowler et al. 
2002). As such, physical activity can play an important role 
in the prevention and management of T2D, and understand-
ing the mechanisms by which physical activity improves 
insulin sensitivity may aid in the optimisation of effective 
non-pharmacological therapies. One mechanism by which 
exercise might improve insulin sensitivity may involve its 
impact on inflammation (Golbidi et al. 2012; Petersen and 
Pedersen 2005). For example, in response to exercise, mus-
cle-derived IL-6 promotes elevated levels of anti-inflam-
matory cytokines, such as IL-10 and IL-1 receptor antago-
nist (IL-1Ra) (Febbraio and Pedersen 2002; Kristiansen 
and Mandrup-Poulsen 2005; Petersen and Pedersen 2005; 
Scheller et al. 2011), potentially inhibiting the actions of 
pro-inflammatory mediators to bring about benefits with 
regard to chronic inflammatory conditions (Golbidi et al. 
2012; Febbraio and Pedersen 2002; Petersen and Pedersen 
2005).
Macrophages are immune cells which exist in almost 
every tissue type (Geissmann et al. 2010). Under certain 
conditions, such as in acute inflammation, macrophage 
populations may be replenished by extravasation of cir-
culating monocytes, which then differentiate into mature 
macrophages within tissues (Ginhoux and Jung 2014; Hal-
dar and Murphy 2014). Macrophages exist in several dif-
ferent phenotypic states, depending on the stimuli to which 
they are exposed (Mantovani et al. 2004); for example, 
interferon-γ (IFN-γ; either alone or in combination with 
microbial ligands or other cytokines e.g., TNFα or MCP-
1) gives rise to ‘classically activated’ M1 macrophages, 
which are characteristically pro-inflammatory, whilst IL-4 
and/or IL-13 stimulation promotes the production of ‘alter-
natively activated’ M2 macrophages, which play regula-
tory and anti-inflammatory roles (Mantovani et al. 2004; 
Mosser and Edwards 2008; Sica and Mantovani 2012). It 
is thought that pro-inflammatory macrophages are major 
instigators of the inflammation which drives insulin resist-
ance (Huang et al. 2010; Osborn and Olefsky 2012; Romeo 
et al. 2012). In support of this, macrophage-specific inhibi-
tion of the IKKβ or JNK pro-inflammatory pathways was 
found to protect against insulin resistance (Arkan et al. 
2005; Han et al. 2013). Furthermore, it has been found that 
macrophages in individuals with obesity and/or T2D are 
skewed towards the M1 phenotype (Chinetti-Gbaguidi and 
Staels 2011; Lumeng et al. 2007; Pradhan Nabzdyk et al. 
2013; You et al. 2013), while deletion of peroxisome pro-
liferator activated receptor gamma (PPARγ), an important 
regulator of M2 polarisation, in murine macrophage cells 
promoted diet-induced systemic insulin resistance and/or 
glucose intolerance (Hevener et al. 2007; Odegaard et al. 
2007). Exercise has also been shown to have a beneficial 
impact on immune cell function within tissues, and on local 
and systemic inflammation. For example, exercise training 
in obese individuals reduced systemic inflammation, spe-
cifically via decreased macrophage infiltration into adipose 
tissue (Bruun et al. 2006) whilst others have demonstrated 
a significant link between the influence of exercise on tis-
sue-macrophages and the pathogenesis of insulin resistance 
(Ikeda et al. 2013; Kawanishi et al. 2010; Oliveira et al. 
2013).
Interestingly, we have previously shown that exercise 
may upregulate PPARγ expression and activity in mixed 
peripheral mononuclear cells (PMNCs; cells which include 
monocytes) (Butcher et al. 2008; Thomas et al. 2012; Yakeu 
et al. 2010). We, and others, have also found that, following 
participation in exercise, macrophages and PMNCs appear 
to adopt a less inflammatory, M2-like phenotype (Ikeda 
et al. 2013; Oliveira et al. 2013; Yakeu et al. 2010). Since 
PPARγ has also been deemed ‘critical’ in priming mono-
cytes for the M2 macrophage phenotype (Bouhlel et al. 
2007), these findings suggest that the insulin-sensitising, 
anti-inflammatory effects of exercise may be attributed, in 
part to its ability to upregulate PPARγ-activity in mono-
cyte/macrophages (Yakeu et al. 2010).
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Therefore, the present research aimed to determine the 
effects of an 8 week, moderate-intensity exercise programme 
on expression of markers of M1 or M2 polarisation in isolated 
human monocytes, and to investigate the mechanisms behind 
any observed changes. We aimed to test the hypotheses that 
such an exercise programme brings about anti-inflammatory 
insulin-sensitising systemic effects within participants; that 
markers of M2 polarisation in primary human monocytes are 
induced following participation in the exercise programme; 
and that PPARγ signalling is increased by exercise, support-
ing a putative role for this signalling molecule in exercise-
associated anti-inflammatory M2 macrophage polarisation.
Materials and methods
Participant recruitment
Exclusion criteria included; a physically active lifestyle 
[assessed using a short version International Physical 
Activity Questionnaire (IPAQ)], a history of cardiovascu-
lar disease (CVD) and any individuals on prescribed lipid-
lowering or metabolism-altering drugs. A power calcula-
tion (Minitab v16) was used to determine that a sample size 
of at least 11 was required for this study. To account for a 
25–30 % attrition rate, it was decided to recruit 19 healthy, 
yet sedentary participants onto the study (convenience sam-
pling resulted in a female only cohort with a mean age of 
42 ± 11 years). Informed consent was obtained from all 
participants and ethics was granted by the School of Health 
Sciences’ School Research Ethics Committee (SREC) at 
Cardiff Metropolitan University, Cardiff, UK.
Pre‑study screening/baseline measures
Body mass, height, BMI and waist circumference were 
measured using standard protocols (Butcher et al. 2008). 
Participant fitness was estimated using the submaximal 
Rockport Fitness Walking Test (Kline et al. 1987), where, 
following a 4 min familiarisation/warm up period, partici-
pants were required to walk as fast as possible for 1 mile 
(1.6 km) on a treadmill (Woodway Desmo, Waukesha, 
USA). Heart rate (HR) upon completion was measured 
using a Polar S410 HR monitor (Polar Electro, Finland) 
and time of completion was taken. VO2max was estimated 
using the following formula (Kline et al. 1987):
VO2max = 132.853−(0.0769 (body mass inpounds))
−(0.3877 (age in years))
+ (6.315 (gender; male = 1, female = 0))
−(3.2649 (time to walk 1 mile in minutes/100ths of minutes))
−(0.1565 (heart rate upon mile completion in beats/minute)).
Estimated VO2max and anthropometric measures were 
taken at baseline and repeated upon completion of the exer-
cise programme, ensuring a 24 h rest period between the 
final exercise session and the VO2max test, in both cases.
Exercise programme design
The exercise programme consisted of three 45 min walk-
ing sessions on a treadmill (Woodway Desmo, Waukesha, 
USA) per week for 8 weeks, totalling 24 fully supervised 
walking sessions. Treadmill walking speeds were set to 
ensure that participants exercised at moderate intensity 
(55–69 % of HRmax; HRmax = 220-age in years) (Bagchi 
and Preuss 2012). In subsequent sessions, HR was moni-
tored using a Polar S410 HR monitor (Polar Electro, Fin-
land) once weekly, at rest and then at 5, 15, 30 and 45 min 
into the exercise session. Throughout programme participa-
tion, walking speed was altered according to changes in HR 
to maintain a constant exercise intensity.
Blood sampling
Participants were fasted for 12 h prior to blood collection 
by venipuncture of the antecubital vein. Blood was col-
lected at four time points; immediately prior to (baseline; 
Wk 0, T0) and immediately following the first exercise 
session (Wk 0, T1) and immediately prior to (Wk 8, T0) 
and immediately following (Wk 8, T1) the final exercise 
session (T0 and T1 indicate pre- or post-exercise, respec-
tively). A 24 h rest period was left between the penultimate 
exercise session and procurement of the ‘Wk 8, T0’ sample.
Serum procurement
Whole blood was collected in plain blood tubes and allowed 
to clot prior to centrifugation for 10 min at 3000×g. Serum 
was stored in aliquots at −80 °C.
Blood fractionation and monocyte purification
Whole blood was collected in EDTA and fractionated via 
density gradient centrifugation using Histopaque®-1077 
(Sigma–Aldrich, Dorset, UK). The mononuclear cell layer 
was collected, washed in isotonic phosphate buffered 
saline (PBS) solution and centrifuged (300×g/10 min) 
to pellet mononuclear cells. An additional platelet wash 
(200×g/10 min) was carried out to remove contaminating 
platelets. Following this, monocytes were isolated via mag-
netic cell isolation using CD14 MACS MicroBeads (Milte-
nyi Biotec, Germany), as per manufacturer’s instructions, 
and monocyte purity was assessed using flow cytometry 
(see online resources ESM). Labelled cells were removed 
from the column and harvested by centrifuged.
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Biochemical analysis
Serum cholesterol, HDL, triglyceride and glucose 
levels were analysed, using an iLab 300 Plus ana-
lyser (Instrumentation Laboratories UK ltd, War-
rington, UK). Serum LDL was quantified indirectly 
using the Friedewald (Friedewald et al. 1972) equation (
[LDL] = [total cholesterol]−[HDL]−
([
triglycerides
]
/2.2
)
 ; 
all values expressed in mmol/l). Serum insulin was meas-
ured using the Invitrogen Insulin Assay Kit, as per manu-
facturer’s instruction (Invitrogen Ltd, Paisley, UK). The 
Berthold Technologies Centro Plate Luminometer (Herts, 
UK) was used to measure luminescence, whilst insulin con-
centrations were determined using MikroWin® software.
Calculation for insulin sensitivity
The McAuley’s score for measuring the insulin sensitiv-
ity index (McAuley’s ISI) was used as a surrogate meas-
ure of insulin resistance. This calculation has been found to 
be suitable for estimations of insulin resistance in normo-
glycaemic individuals, such as the participants within this 
study (Ascaso et al. 2003; McAuley et al. 2001). McAu-
ley’s ISI was calculated as follows:
where I0 = fasting insulin (mU/l), BMI = body mass index 
(kg/m2), TG = fasting triglycerides (mmol/l).
RNA isolation/RT‑PCR
TRI reagent® (Applied Biosystems, Warrington, UK) was 
used to obtain RNA from monocyte samples, as per man-
ufacturer’s instructions. RNA quantity and quality were 
assessed using the NanoDrop® ND-1000 spectrophotom-
eter (Thermo Fisher Scientific, Leicester, UK) and RNA 
was converted into cDNA using a High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, War-
rington, UK), as per manufacturer’s instructions. Gene 
expression was carried out on an Applied Biosystems Fast 
7500 Real-Time PCR System (Warrington, UK) using Fast 
SYBR® Green or TaqMan® Fast Universal (No AmpEr-
ase® UNG) methodologies. For Fast SYBR® Green, prim-
ers were designed using National Center for Biotechnology 
Information’s ‘Primer-BLAST’ primer designing tool, and 
made to order (Sigma–Aldrich, Dorset, UK). The following 
primer sequences were used:
Dectin-1. Fwd: 5′- GGAAGCAACACATTGGAGA-
ATGG-3′; Rev: 5′- CTTTGGTAGGAGTCACACT-
GTC-3′
McAuley’s ISI = exp [3.29− 0.25× ln(I0)− 0.22
× ln(BMI)− 0.28× ln(TG)]
IL-10. Fwd: 5′-ACGGCGCTGTCATCGATT-3′; Rev: 
5′-TTGGAGCTTATTAAAGGCATTCTTC-3′
IL-1Ra. Fwd: 5′-GGCCTCCGCAGTCACCTAATCAC-3′; 
Rev: 5′-GGACAGGCACATCTTCCCTCCAT-3′
TNFα. Fwd: 5′-TGCCTGCTGCACTTTGGAGTGA-3′; 
Rev: 5′- CTGGGCCAGAGGGCTGATTAGAGA-3′
CD36. Fwd: 5′-GGAAGTGATGATGAACAGCAGC-3′; 
Rev: 5′- GAGACTGTGTTGTCCTCAGCGT-3′
LXRα. Fwd: 5′-CGCACTACATCTGCCACAGT-3′; 
Rev: 5′-TGAGGCGGATCTGTTCTTCT-3′
ABCA1. Fwd: 5′-GCACTGAGGAAGATGCTGAAA-3′; 
Rev: 5′-AGTTCCTGGAAGGTCTTGTTCA-3′
COX-2. Fwd: 5′-TGAAACCCACTCCAAACACA-3′; 
Rev: 5′-GAGAAGGCTTCCCAGCTTTT-3′
GAPDH. Fwd: 5′-CATTGACCTCAACTACATG-3′; 
Rev: 5′-TCTCCATGGTGGTGAAGAC-3′.
Alternatively, TaqMan® RT-PCR was used to determine 
MCP-1, IL-4 receptor α (IL-4Rα) and PPARγ gene expres-
sion. For TaqMan® experiments, pre-designed PrimeTime® 
Assays (Integrated DNA Technologies, Iowa, USA) which 
detected all genetic variants but not genomic DNA and 
those in which exon boundaries were consolidated were 
selected for use (assay configuration: 6-FAM/ZEN/IBFQ, 
P:P 2.0). A non-template control (NTC; nuclease free 
water instead of cDNA) was included for each gene ana-
lysed. The comparative CT method was used to calculate 
gene expression relative to the reference sample. Data were 
only included if plots of log[RNA] versus ΔCT resulted 
in slopes of between −0.1 and +0.1, meaning that ampli-
con efficiencies were approximately equal, and if plots of 
log template versus CT gave slopes of approximately −3.3 
(representing 100 % PCR efficiency). Baseline samples, 
i.e., those taken prior to the 8 week exercise programme, 
were used as reference samples.
Gene reporter assays
Two gene reporter assays were conducted to investigate 
(1) the PPARγ activating properties of serum (‘PPRE-
Luc’) and (2) PPARγ ligand availability (‘PPARγ-LBD’) 
in serum samples obtained from study participants. Human 
embryonic kidney (HEK-293T) cells (ATCC, Middlesex, 
UK) were maintained under standard conditions in DMEM 
(Invitrogen Ltd, Paisley, UK), supplemented with 10 % 
US Defined, Irradiated and Heat inactivated Fetal Bovine 
serum (FBS; Thermo Fisher Scientific, Leicester, UK), 
100 U/mL penicillin/100 μg/mL streptomycin mix and 
4 mM l-glutamine (Invitrogen Ltd, Paisley, UK). Cells 
were seeded in opaque 96-well plates at 2 × 105 cells/well 
and incubated in a 37 °C, 5 % CO2, humidified incubator 
for 24 h prior to transient transfection.
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PPRE‑Luc
Cells were transfected with 100 ng of each of the PPRE-
luciferase reporter construct and the PPARγ expres-
sion vector and 2 ng of the Renilla plasmid, using Lipo-
fectamine® LTX Reagent (Invitrogen Ltd, Paisley, UK) 
according to manufacturer’s instructions and as previously 
described (Thomas et al. 2012). Cells were incubated 
with plasmids in a 37 °C, 5 % CO2, humidified incubator 
for a further 24 h, following which media was removed 
and replaced with plasma samples [normalised for protein 
content and added at 10 % (v/v) to DMEM (minus FBS)]. 
Alternatively cells were treated with 1 µM rosiglitazone 
(a known activator of PPARγ) as a positive control. After 
24 h, cells were harvested and lysed and luminescence 
was analysed using the Dual-Luciferase® Reporter Assay 
System (Promega, Southampton, UK) as per manufac-
turer’s instructions. Luminescence values were normalised 
with regard to transfection efficiency by use of a ratio of 
Luciferase:Renilla luminescence and reported as relative 
light units (RLU).
PPARγ‑LBD
Cells were transfected with 2 μg of a fusion vector carry-
ing the PPARγ-LBD fused with the GAL4 DNA-binding 
domain (DBD) [PPARγ-LBD/GAL4-DBD; (Tzameli et al. 
2004)], 2 μg of an Upstream Activation Sequence (UAS; 
GAL4 response element)-luciferase reporter construct 
[UAS; (Collingwood et al. 1997)] and 0.5 μg of β-gal, 
diluted in 1.5 mL unsupplemented DMEM and mixed 
with TransFastTM Transfection Reagent (Promega, South-
amptom, UK) in a 3:1 charge ratio of TransFast™ (μL) to 
DNA (μg). The TransFast™-plasmid mix was incubated 
for 10 min before cells were incubated with the plasmids 
in a 37 °C, 5 % CO2, humidified incubator for 1 h, before 
2.5 mL of supplemented DMEM media (minus antibiot-
ics) was added to cells. Cells were incubated with plasmids 
for a further 24 h, following which media was removed 
and replaced with plasma samples [normalised for pro-
tein content and added at 10 % (v/v) to DMEM (minus 
FBS)]. Alternatively cells were treated with 1 µM rosigli-
tazone (a known activator of PPARγ) as a positive control. 
After 24 h, cells were harvested and lysed and 40 μL of 
each lysate was transferred to the wells of an opaque 96 
well plate and 50 μL of LAR II was auto-injected into each 
well and luminescence readings were taken using a Tecan 
Infinite 200 plate reader. Simultaneously, for internal con-
trol (β-gal) readings, 40 μL of each lysate was transferred 
into wells of a transparent 96-well plate and an equal vol-
ume of o-Nitrophynyl-beta-d-galactopyranosidase (ONPG; 
β-gal substrate) was added to wells, incubating for 30 min, 
or until a yellow colour developed. Absorbance was read 
using the Tecan Infinite 200 plate reader, set at 435 nm. The 
ratio of Luciferase luminescence to β-gal OD was used to 
normalise values, and values were reported as RLU.
ELISA
Commercially available ELISA kits were used according 
to manufacturer’s instructions to determine serum cytokine 
levels; the Human IL-4 High Sensitivity ELISA (eBiosci-
ence, Vienna, Austria) was used to quantify IL-4 and The 
RayBio® Human IL-13 ELISA Kit (Insight Biotechnology 
Ltd, Middlesex, UK) was used to quantify IL-13 in ‘Wk 0, 
T0’ and ‘Wk 8, T0’ serum samples, whilst the Quantikine® 
HS ELISA Human IL-6 Immunoassay (R&D Systems, 
Abington, UK) was used to quantify serum IL-6 in ‘Wk 0, 
T0’ and ‘Wk 0, T1’ serum samples. Spectrophotometry was 
carried out on a Tecan Infinite 200 (Tecan, Reading, UK).
Statistical analysis
All data were expressed as mean ± standard deviation 
(SD), unless otherwise stated. Where comparisons were 
made between the means of two samples, t tests or Wil-
coxon’s pairwise analysis were used, depending on data 
distribution (the D’Agostino and Pearson omnibus normal-
ity test was used to test for normal distribution of data). 
Alternatively, one-way analysis of variance (ANOVA) with 
Tukey’s post hoc analysis was used for multiple compari-
sons within groups of normally distributed data. Statistical 
analysis was performed using GraphPad Prism®5 software 
and results were deemed significant at p < 0.05.
Results
The effect of an 8‑week moderate‑intensity walking 
programme on cardio‑metabolic risk markers
Nineteen healthy, yet sedentary female participants were 
recruited onto the study (mean age of 42 ± 11 years; 
body weight 76.54 ± 12.54 kg; body mass index (BMI) 
29.7 ± 5.1 kg/m2; waist circumference 91.74 ± 13.36 cm; 
systolic blood pressure 126.3 ± 9.9 mmHg; diastolic blood 
pressure 78.5 ± 8.8 mmHg. As shown in Table 1, mean 
body mass was significantly reduced following partici-
pation in the exercise intervention [p < 0.05 compared to 
baseline (‘Wk 0, T0’)], as was BMI (p < 0.05) and waist 
circumference (p < 0.01). Furthermore, systolic blood pres-
sure showed a non-significant decrease (p = 0.059) and 
diastolic blood pressure was unaltered. Additionally, there 
was a significant increase in estimated VO2max (p < 0.01).
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No significant changes were identified in serum 
total cholesterol, LDL or HDL. However, median lev-
els of serum triglycerides were significantly reduced post 
intervention, when compared to baseline (‘Wk 0, T0’) 
(p < 0.01). Additionally, there was a significant increase in 
insulin sensitivity, as measured by McAuley’s ISI, when 
compared to baseline (p < 0.05, see Table 1).
Markers of M1/M2 polarisation were significantly 
altered in monocytes following an 8‑week 
moderate‑intensity walking programme
The M2 marker genes Dectin-1 and IL-10 were sig-
nificantly upregulated by 2.6 ± 1.9-fold (p < 0.01) and 
3.0 ± 2.8-fold, respectively (p < 0.05; Fig. 1). mRNA 
expression of IL-1Ra was also elevated by 1.3 ± 0.7-
fold, showing a non-significant trend towards increased 
expression (p = 0.099). Conversely, the M1 marker, MCP-
1, was significantly reduced to approximately 0.83 ± 0.2 
(p < 0.05) of baseline (‘Wk 0, T0’) expression, following 
participation in the exercise intervention [in contrast, TNFα 
was significantly upregulated by 2.2 ± 1.4-fold (p < 0.01)].
PPARγ activity was increased in monocytes 
following an 8‑week moderate‑intensity walking 
programme, potentially due to acute exercise‑induced 
increases in the PPARγ‑activating properties of serum
The effects of exercise on PPARγ were investigated to pro-
vide a potential mechanism for the increase in M2 marker 
expression observed in monocytes in response to the exer-
cise intervention. Although PPARγ mRNA expression 
did not alter significantly in monocytes following exer-
cise training, when compared to baseline (‘Wk 0, T0’) 
(Fig. 2a), monocytic expression of the PPARγ-regulated 
downstream target genes, CD36 (1.9 ± 1.5-fold, p < 0.05), 
Table 1  Physiological and biochemical parameters at baseline (Wk 
0, T0) and after 8 weeks (Wk 8, T0) of exercise participation
Results are shown as mean ± SD with changes from baseline 
(Δ) presented with 95 % CI of the mean. n = 19 for all the cases 
except for VO2max, where n = 15 (for n = 4, baseline VO2max levels 
were below the measurable range) and blood lipids and McAuley’s 
ISI, where n = 17 (for n = 2, blood lipid levels were undetectable). 
*p < 0.05, **p < 0.01, paired t test was used for all the analysis other 
than fasting insulin, glucose, and blood lipids, where Wilcoxon’s 
paired analysis was used
Wk 0, T0 Wk 8, T0 Δ (95 % CI)
Weight (kg) 76.5 ± 12.5 75.7 ± 12.4 −0.9 (−1.63, 
−0.09)*
BMI (kg/m2) 29.7 ± 5.1 29.4 ± 4.9 −0.4 (−0.67, 
−0.04)*
Waist  
circumference 
(cm)
91.7 ± 13.4 86.2 ± 12.0 −5.6 (−8.09, 
−3.05)**
Systolic BP 
(mmHg)
126.3 ± 9.9 121.2 ± 12.0 −5.1 (−10.36, 
−0.21)
Diastolic BP 
(mmHg)
78.4 ± 7.8 77.8 ± 10.9 −0.6 (−4.78, 3.52)
VO2max (mL/kg/
min)
26.8 ± 8.2 34.7 ± 5.3 −7.9 (4.95, 
10.84)**
Total cholesterol 
(mmol/L)
4.8 ± 0.9 5.0 ± 1.1 −0.2 (−0.17, 0.47)
LDL (mmol/L) 2.6 ± 0.7 2.9 ± 0.8 −0.2 (−0.01, 0.49)
HDL (mmol/L) 1.6 ± 0.4 1.6 ± 0.4 −0.0 (−0.09, 0.07)
Triglycerides 
(mmol/L)
1.3 ± 0.5 1.1 ± 0.5 −0.2 (−0.34, 
−0.02)**
Fasting glucose 
(mmol/L)
4.8 ± 0.5 4.7 ± 0.5 −0.1 (−0.38, 0.15)
Fasting insulin 
(pmol/L)
49.9 ± 54.0 34.2 ± 19.9 −15.7 (−37.50, 
6.12)
McAuley’s ISI 
(M/mU/L)
8.2 ± 2.2 9.1 ± 2.2 −0.98 (−0.0009, 
1.96)*
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Fig. 1  Effect of an 8 week, moderate-intensity exercise interven-
tion on gene expression of M2 markers and M1 markers in human 
monocytes. Isolated human monocytes were obtained at baseline 
(Wk 0, T0) and prior to the final exercise session (Wk 8, T0) of an 
8 week, moderate-intensity walking programme. Where possible, 
the baseline values for each individual were used as comparators. 
In some cases, RNA quality or quantity was not sufficient for use in 
RT-PCR or some genes of interest were expressed at levels below the 
acceptable range of the assay and so were excluded from analysis 
(IL-10, n = 10; Dectin-1, n = 14; IL-1Ra, n = 14; MCP-1, n = 8; 
TNFα, n = 14; values expressed as fold gene expression relative to 
GAPDH ± SEM; *p < 0.05, **p < 0.01, t test)
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Liver X receptor α (LXRα; 5.0 ± 4.7-fold, p < 0.01), and 
ABCA1 (1.5 ± 1.9-fold, p > 0.05) was increased (Fig. 2a). 
In addition, the expression of cyclooxygenase-2 (COX-2), 
an enzyme associated with the generation of intracellular 
PPARγ ligands (Díaz-Gandarilla et al. 2013), was also sig-
nificantly upregulated in monocyte samples obtained prior 
to the final exercise session, when compared to baseline 
(‘Wk 0, T0’) (3.6 ± 2.7-fold, p < 0.01; Fig. 2a).
To investigate potential mechanisms for exercise-
induced PPARγ activation, gene reporter assays were 
used to analyse the PPARγ-activating properties of serum 
and PPARγ ligand generation in serum samples obtained 
throughout the exercise study. Figure 2b demonstrates that 
the PPARγ-activating properties of serum (as measured 
using PPRE-luciferase reporter assay) were significantly 
increased compared to baseline (‘Wk 0, T0’) immedi-
ately following individual exercise bouts (‘Wk 0, T1’: 
1.16 ± 0.19-fold RLU; ‘Wk 8, T1’: 1.17 ± 0.25-fold RLU,-
fold values relative to baseline (‘Wk 0, T0’), p < 0.05), 
while the PPARγ activating properties of serum underwent 
a non-significant increase over the duration of the entire 
exercise training programme [‘Wk 8, T0’: 1.14 ± 0.24-
fold RLU, fold relative to baseline (‘Wk 0, T0’)]. Interest-
ingly, however, neither acute exercise nor exercise training 
significantly altered ligand generation, as measured by the 
PPARγ-LBD gene reporter assay, [Fig. 2c; ‘Wk 0, T1’; 
1.09 ± 0.26-fold RLU; ‘Wk 8. T0’: 0.94 ± 0.30-fold RLU; 
‘Wk 8, T1’: 0.97 ± 0.26-fold RLU, fold values relative to 
baseline (‘Wk 0, T0’)].
Elevations in IL‑6 were observed after individual 
exercise bouts; however, alterations in IL‑4 or IL‑13 
were not detected over the duration of an 8‑week 
moderate‑intensity walking programme
In the present study, levels of the M2-promoting stimu-
lus, IL-4, were non-detectable in serum samples obtained 
either at baseline (‘Wk 0, T0’) or at the final exercise ses-
sion (‘Wk 8, T0’) (minimum detection levels of the assay 
were 0.25 pg/mL; data not shown), whilst serum levels 
of another M2 stimuli, IL-13, did not alter significantly 
over the course of the exercise programme (‘Wk 0, T0’: 
10.52 ± 3.43 pg/mL; Wk 8, T0: 11.20 ± 3.47 pg/mL; see 
Fig. 3a). Serum IL-6 concentrations increased significantly 
immediately after individual exercise bouts (‘Wk 0, T0’: 
1.20 ± 0.21 pg/mL vs ‘Wk 0, T1’: 1.63 ± 1.32 pg/mL, 
p < 0.01, see Fig. 3b); however, baseline (‘Wk 0, T0’) lev-
els of serum IL-6 were not altered over the duration of the 
8 week exercise programme (results not shown).
Discussion
Previously, our group has demonstrated an increased 
M2 marker expression in human PMNCs following par-
ticipation in an 8 week walking intervention (Yakeu et al. 
2010). Since monocytes may be ‘primed’ for differentia-
tion into specific M1 or M2 macrophage states (Bouhlel 
et al. 2007), it was deemed important to determine whether 
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Fig. 2  Effect of an 8 week, moderate-intensity exercise interven-
tion on monocyte expression/activity of PPARγ and mechanisms for 
PPARγ activation. a Monocytes were obtained at baseline (Wk 0, T0) 
and immediately prior to the final exercise session (Wk 8, T0) of an 
8 week, moderate-intensity walking programme and gene expression 
of PPARγ and PPARγ-associated genes, CD36, LXRα, ABCA1, and 
COX-2, was analysed. The baseline values for each individual were 
used as comparators. Gene reporter assays were used to analyse b the 
PPARγ activating properties of serum and c PPARγ ligand availably 
in serum obtained at baseline (Wk 0, T0), immediately following the 
initial exercise bout (Wk 0, T1), immediately prior to the final exer-
cise bout (Wk 8, T0), and immediately following the final exercise 
bout (Wk 8, T1) of an 8 week, moderate-intensity exercise interven-
tion. Rosiglitazone (RSG) was used as positive control luminescence 
values that were normalised to an internal control vector to obtain 
RLU values corresponding to PPARγ activity (RT-PCR: PPARγ, 
n = 10; LXRα and ABCA1, n = 9; CD36, n = 16; COX-2, n = 12; 
values expressed as fold gene expression relative to GAPDH ± SEM, 
*p < 0.05, **p < 0.01, t test. Gene reporter assays: n = 19 for serum, 
n = 3 for RSG; values expressed as fold RLU ± SD, *p < 0.05, 
**p < 0.01, one-way ANOVA)
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the previously observed effect of exercise on M2 marker 
expression occurs specifically within monocytes. This 
study demonstrates that participation in an 8 week, moder-
ate-intensity brisk walking intervention upregulated mark-
ers of alternative activation in circulating monocytes and 
improved systemic insulin sensitivity, and provided evi-
dence for a role for PPARγ as a putative mediator of these 
exercise-induced effects.
Specifically, the monocyte M2 markers, IL-10, Dectin-1, 
and IL-1Ra, were found to increase following the exercise 
intervention (see Fig. 1); mRNA expression of IL-10 and 
Dectin-1 was significantly elevated, whereas the increase 
in IL-1Ra expression approached significance. In con-
trast, the gene expression of the M1 marker, MCP-1, sig-
nificantly decreased to ~0.8-fold of basal levels, which is 
in agreement with the previous findings (Kawanishi et al. 
2010; Oliveira et al. 2013; Yakeu et al. 2010). However, 
the expression of the M1 marker, TNFα, was significantly 
elevated by ~twofold (Fig. 1). Interestingly, the profile of 
polarisation markers expressed by monocytes following 
exercise training in the current study is representative of a 
specific M2 macrophage subtype; the ‘M2b’ macrophage 
subset, which are said to produce M1-associated cytokines 
(including TNFα) but also high levels of IL-10, causing 
M2b cells to be immuno-regulatory (Hao et al. 2012; Khar-
raz et al. 2013; Mantovani et al. 2004). However, additional 
research would be required to substantiate the speculation 
that exercise training drives monocytes into an M2b phe-
notype. To our knowledge, this study is the first to dem-
onstrate that exercise training increases markers of M2 
polarisation specifically within monocytes, in a way which 
may drive them towards differentiation into the M2 mac-
rophage phenotype, regarded as beneficial in the prevention 
of insulin resistance and T2D (67). However, at this stage, 
it should not be assumed that the significant improvement 
observed in insulin sensitivity (Δ0.98 M/mU/L compared 
to baseline, p < 0.05) in this study was solely a result of the 
changes in monocytic expression of M1/M2 markers in the 
present study (Table 1). Furthermore, it is well known that 
moderate exercise significantly lowers triglycerides, as was 
the case in this study, and this may also be an important 
contributing factor to the observed improvement in insulin 
sensitivity (Kraus and Slentz 2009).
We have previously shown that both acute and chronic 
exercise may induce the activation of PPARγ, a transcrip-
tion factor thought to play an important role in prim-
ing monocytes for M2 polarisation (Bouhlel et al. 2007; 
Butcher et al. 2008; Thomas et al. 2012; Yakeu et al. 2010). 
However, this has only been demonstrated in mixed mon-
onuclear cells (Butcher et al. 2008; Thomas et al. 2012; 
Yakeu et al. 2010), and has not yet been investigated within 
isolated monocytes. The findings from the current study 
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Fig. 3  Serum IL-13 and IL-6 concentration in response to an 8 week, 
moderate-intensity brisk walking intervention. a Serum IL-13 and 
b serum IL-6 were measured via ELISA. Serum IL-13 concentra-
tion was measured in samples taken at baseline (Wk 0, T0) and 
immediately prior to the final bout of an 8 week, moderate-intensity 
exercise intervention (Wk 8, T0), whereas serum IL-6 was meas-
ured in samples taken at baseline (Wk 0, T0) and following an acute 
bout of moderate-intensity exercise (Wk 0, T1) [IL-13, n = 17 (for 
n = 2, IL-13 levels were below the detection limit of the assay); 
IL-6, n = 19; results expressed as individual data points; significance 
related to mean values; **p < 0.01, paired t test]
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suggest that PPARγ activity was elevated in monocytes in 
response to exercise training: PPARγ downstream genes, 
namely, CD36, LXRα and COX-2, were significantly 
upregulated after the 8 week intervention when compared 
to baseline, while ABCA1 underwent a non-significant 
increase (see Fig. 2a). CD36 is also associated with the 
M2 macrophage phenotype (Bouhlel et al. 2007; Oh et al. 
2012) and so its upregulation may be used to further sup-
port the impact of exercise on monocyte activation.
To further investigate the mechanism(s) by which exer-
cise may have enhanced monocyte PPARγ activity, both 
serum PPARγ activating properties and serum PPARγ 
ligand availability were determined using gene reporter 
assays. The PPARγ-activating properties of serum were 
shown to increase acutely upon exercise (Fig. 2b), despite 
no changes in PPARγ expression (Fig. 2a) or serum PPARγ 
ligand availability in response to acute or chronic physi-
cal activity (Fig. 2c). These results are in accordance with 
those we obtained previously and provide further evidence 
that exercise promotes PPARγ activation (Thomas et al. 
2012). While the serum ligand availability assays demon-
strate that this effect is independent of exogenous ligand 
production, our data suggest that exercise may instead trig-
ger endogenous PPARγ ligand generation, as exercise-asso-
ciated elevations in monocyte COX-2 expression (Fig. 2a) 
may contribute to increased PPARγ activity within mono-
cytes, since COX-2 encodes an inducible enzyme which 
is responsible for the production of endogenous PPARγ 
ligands (e.g., 15d-PGJ2) (Díaz-Gandarilla et al. 2013; Heu-
sinkveld et al. 2011; Sica and Mantovani 2012). In addi-
tion, exercise participation may trigger ligand-independent 
post-translational modifications of PPARγ, such as phos-
phorylation or sumoylation, resulting in PPARγ activation 
(Harmon et al. 2011; Olefsky and Glass 2010). However, it 
is a limitation of the current study that the specific PPARγ 
activating factor(s) responsible for this effect was not iden-
tified. In addition, the model system used in these experi-
ments (HEK293-T cells) may not express the relevant 
ligand uptake/processing machinery, and thus, the in vivo 
situation may not be accurately reflected by these results. 
Future work would benefit from using cells which more 
closely resemble human monocytes.
It is also possible that exercise-induced alterations in 
systemic cytokine levels may impact upon PPARγ activ-
ity and M1/M2 marker expression in monocytes. Despite 
no observed change in serum levels of the established 
M2-stimuli IL-4 (data not shown) and IL-13 (Fig. 3a) 
(Mantovani et al. 2004) following exercise training, IL-6 
was found to be significantly elevated in serum immedi-
ately following participation in exercise bouts (Fig. 3b). 
IL-6 is known to be synthesised by contracting muscle dur-
ing acute exercise (Pan et al. 2012; Dishman et al. 2013); 
accordingly serum levels of IL-6 are transiently elevated 
upon exercise participation (Pedersen and Febbraio 2008), 
rapidly returning to baseline within 1–2 h of exercise ces-
sation (Gleeson et al. 2011; Moldoveanu et al. 2000). 
Recently, an interesting role for IL-6 in the alternative acti-
vation of monocytes has been revealed: Mauer et al. dem-
onstrated that IL-6 is required for IL-4-dependent M2 mac-
rophage polarisation, and that the depletion of the IL-6Rα 
chain of the IL-6 receptor in myeloid cells induced insulin 
resistance and impaired glucose homeostasis (Mauer et al. 
2014). Moreover, IL-6 was shown to upregulate IL-4 recep-
tor (IL-4Rα) expression in macrophages, making these 
cells more sensitive to IL-4 stimulation. In addition, Szanto 
et al. (2010) demonstrated that IL-4/STAT-6 signalling 
resulted in augmented PPARγ activation in macrophages 
independent of changes in ligand availability. Thus, it may 
be speculated that in the present study, exercise IL-6-in-
duced upregulation of IL-4Rα and subsequent increased 
sensitivity to IL-4 may contribute to the observed exercise-
associated monocyte PPARγ activation (Fig. 2c), independ-
ent of changes in PPARγ ligand availability.
We acknowledge that a major limitation of this research 
is its reliance on the assumption that the M2 monocyte 
phenotype is retained upon extravasation and differen-
tiation into tissue macrophages, whereas the possibility of 
intra-tissue ‘switching’ of macrophage phenotype has been 
previously reported (Dalmas et al. 2011; Lee et al. 2013). 
Thus, further investigations are required to elucidate the 
effects of similar exercise interventions on M1:M2 ratio 
in various tissue environments. Nevertheless, it should be 
noted that, if a link can be made between the classification 
of monocytes and that of macrophages, the current research 
may facilitate the use of monocytes (which are easily 
accessible cells) as biomarkers for macrophage-associated 
diseases, such as T2D.
Importantly, regardless of the specific PPARγ-activating 
process/es, exercise-associated increases in PPARγ-
activating properties of serum may contribute to the sys-
temic beneficial effects of the current exercise programme 
with regard to insulin sensitivity (Table 1). We propose that, 
in a similar way to PPARγ-targeting anti-diabetic agents, 
exercise participation may increase levels of blood-borne 
PPARγ-activating factors, allowing for sustained systemic 
PPARγ activation in a range of cells and tissues, and this 
may, together with many other contributing factors, impact 
upon glucose metabolism, lipid homeostasis, and inflam-
mation within these tissues (Harmon et al. 2011; Wahli and 
Michalik 2012). In addition, we would contend that these 
findings further support the use of exercise prescription as 
an alternative to currently available pharmacological thera-
pies with regard to the management and treatment of T2D 
and its cardiovascular complications.
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Conclusions
In conclusion, participation in an 8 week, moderate-inten-
sity exercise programme induces M2 marker expression and 
PPARγ activation in monocytes (potentially priming them 
for differentiation into M2-polarised tissue macrophage) and 
exerts beneficial systemic effects with regard to insulin resist-
ance. In addition to the observed beneficial alterations in key 
predictors of cardio-metabolic risk, including body weight, 
BMI, waist circumference, triglycerides, aerobic capacity, 
and insulin sensitivity, the current study provides further evi-
dence that the prescription of a moderate-intensity walking 
programme may be beneficial to the prevention of T2D and 
its cardiovascular complications in at risk populations.
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